Metropolis Healthcare shares traded higher on Thursday after the company’s management maintained a bullish growth outlook for FY27 despite a Q4 miss, with investors taking note of strong year-on-year growth in profit, revenue, EBITDA and margins.
The stock was trading at Rs 554.50, up 1.19% or Rs 6.50 as of 10:04 AM. Metropolis Healthcare had opened higher and moved in a day range of Rs 553.05 to Rs 600.00. The previous close stood at Rs 548.00.
The stock also touched its 52-week high of Rs 600.00 during the session, while its 52-week low stands at Rs 397.08. The company’s market capitalisation stood at Rs 115.51 billion, with an average volume of 550.74K.
The positive move came after the company’s management, in its concall update, confirmed a 13% to 15% growth target for 2027, despite the Q4 miss.
For Q4 FY26, Metropolis Healthcare reported a net profit of Rs 51 crore, compared with Rs 29 crore in the corresponding quarter last year, marking a year-on-year increase of around 131.8%.
Revenue on a consolidated basis rose 23% year-on-year to Rs 425 crore, compared with Rs 345 crore in the same period last year.
The company’s EBITDA increased 73.4% year-on-year to Rs 108 crore, compared with Rs 62.3 crore a year ago. EBITDA margin also improved to 25.4%, compared with 18% in the corresponding quarter last year.
Operationally, the company reported 11% year-on-year growth in patient volumes, while test volumes increased 14% year-on-year. B2C revenues rose 20% year-on-year, supported by higher adoption of preventive and specialised testing, stronger digital engagement and hyperlocal marketing initiatives.
B2B revenues increased 28% year-on-year, helped by client retention, hospital outsourcing opportunities, stronger partner relationships and improved service reliability.
Metropolis Healthcare also reported growth in key portfolios. The TruHealth portfolio grew 24% year-on-year, while the specialty portfolio rose 31% year-on-year, reflecting higher demand for preventive healthcare and advanced diagnostics.
Revenue per patient improved 11% year-on-year, while revenue per test increased 8% year-on-year, supported by a favourable mix and higher contribution from specialised testing.
The company also crossed the milestone of 5,000 plus centres across India, strengthening its accessibility and market presence.
Metropolis Healthcare declared a second interim dividend of Rs 1 per equity share of face value Rs 2 for FY26 and fixed Tuesday, May 19, 2026, as the record date.
Overall, Metropolis Healthcare shares moved higher as investors focused on strong YoY earnings growth, margin expansion, network expansion and management’s 13% to 15% FY27 growth guidance, despite the Q4 miss.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Fingo is not liable for any losses arising from the use of this information.